Could epilepsy and blood disorder drugs take on brain cancer?

NCT ID NCT07284069

Recruiting now Disease control Sponsor: Aarhus University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests two existing drugs—senicapoc and perampanel—alone and together in 36 adults with newly diagnosed glioblastoma, the most common and aggressive brain cancer. The goal is to find safe doses and see how well the drugs reach the brain and affect tumor cells. Participants receive standard treatment plus the study drugs, with close monitoring for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: senicapoc and perampanel
What this could lead to: If successful, this could point toward a new treatment combination that slows glioblastoma growth and makes standard therapy more effective.
What could go wrong: This is a very early, small trial with only 36 patients. The drugs may not reach the tumor effectively or could cause side effects. Success in this phase does not guarantee benefit in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Aarhus University Hospital, Department of Neurosurgery
RECRUITING

Aarhus, Denmark, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.